| Type | Aktiengesellschaft |
|---|---|
| Traded as | WBAG: ICLL |
| Industry | Biotechnology |
| Founded | 1998 |
| Headquarters | Vienna, Austria |
| Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Revenue | €34.2 million (2010)[1] |
| Operating income | (€251.2 million) (2010)[1] |
| Profit | (€255.2 million) (2010)[1] |
| Total assets | €225.2 million (end 2010)[1] |
| Total equity | €121.1 million (end 2010)[1] |
| Employees | 410 (average, 2010)[1] |
| Website | www.intercell.com |
Intercell AG is a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[2] It employs 400 people in Austria, Scotland and the United States.
It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.[3][4]
Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.
The most important projects of Intercell are: